Full-Time

Executive Director

Digital Enablement

Vaxcyte

Vaxcyte

501-1,000 employees

Develops broad-spectrum vaccines for bacterial infections

Compensation Overview

$288k - $335k/yr

+ Equity component

San Carlos, CA, USA

Remote

Remote role with 20% travel; relocation assistance is available.

Bachelor's, Master's, MBA

Category
Business & Strategy (1)
Required Skills
LLM
Veeva
Product Management
CRM
Salesforce
Data Analysis

Get referred to Vaxcyte

See people who can refer or advise you

Requirements
  • A Bachelor of Arts or Bachelor of Science degree in a scientific discipline, business, marketing, or technology is required; other combinations of education and experience may be considered.
  • A minimum of 15 years of industry-related experience is required, including at least 5 years in commercial or commercial-facing roles within pharmaceutical, biotech, or vaccine organizations and direct exposure to product launch.
  • Demonstrated product management experience, including owning a product roadmap, managing a backlog, working in iterative delivery cycles, and measuring outcomes.
  • Experience building or leading a commercial digital or commercial excellence function with accountability for adoption and business results, not just technical delivery.
  • Deep understanding of the commercial technology ecosystem, including customer relationship management systems, marketing automation platforms, data and analytics platforms, and healthcare professional-facing digital channels.
  • Deep understanding of frontier artificial intelligence models and their applications in business.
  • Proven ability to translate commercial strategy into technical requirements and technical constraints into business options.
  • Working knowledge of generative artificial intelligence, predictive analytics, next-best-action tools, and artificial-intelligence-assisted content workflows.
  • Familiarity with revenue management infrastructure, including chargebacks, rebates, and gross-to-net systems.
  • Familiarity with Sunshine Act compliance, medical, legal, and regulatory review workflows, and promotional materials management.
  • Ability to travel 20% of the time for commercial and cross-functional team engagements.
Responsibilities
  • Develop a phased commercial digital vision for the United States adult launch covering pre-launch, launch, and growth phases, with defined milestones and measurable outcomes.
  • Own and maintain a commercial product roadmap treating each digital capability as a discrete product with a use case, user, success metric, and release schedule.
  • Map the end-to-end commercial experience from account manager and field representative perspectives through provider and executive touchpoints, identifying sources of digital leverage and unnecessary complexity.
  • Define and prioritize artificial intelligence use cases for field force effectiveness, marketing operations, customer segmentation, content production, and performance analytics based on business impact and data readiness.
  • Ensure technology decisions follow defined commercial use cases, with architecture following strategy and vendor selection following requirements.
  • Serve as the commercial voice in digital and technology planning conversations so that field, marketing, Medical Affairs, Market Access, and commercial operations priorities drive decisions.
  • Translate commercial strategy into requirements that information technology, vendors, and data teams can implement, and translate technical constraints and trade-offs into actionable business options.
  • Partner with Marketing to build the marketing technology stack, performance marketing capability, and content infrastructure, and streamline medical, legal, and regulatory review workflows.
  • Partner with Sales and Field Force Excellence to equip the field with customer relationship management, call planning, territory management, and mobile tools.
  • Partner with Medical Affairs to build digital engagement, scientific exchange, congress engagement, and key opinion leader mapping capabilities.
  • Partner with Market Access and Commercial Operations to establish contract management, chargeback, revenue management, and Sunshine Act compliance workflows.
  • Serve as the primary liaison to the Information Technology Commercial Lead, ensuring technology implementation aligns with commercial strategy.
  • Define and lead the artificial intelligence capability roadmap for commercial and Medical Affairs organizations.
  • Deploy artificial-intelligence-powered strategic tools for commercial leadership, including virtual advisory simulations, pressure-testing frameworks, and intelligence briefing workflows.
  • Champion artificial intelligence literacy and adoption across commercial functions.
  • Establish artificial intelligence governance guardrails for commercial contexts in partnership with Legal and Compliance.
  • Lead commercial evaluation of customer relationship management, marketing automation, data, and artificial intelligence vendor options, distinguishing what to build, buy, or rent.
  • Maintain a composable, modular platform philosophy in which components can be replaced without requiring a full stack rebuild.
  • Ensure vendor contracts entered by the Information Technology Commercial Lead receive commercial sign-off on scope, functionality, and success criteria.
  • Define the commercial data strategy, including required data, procurement timing, activation, and governance across customer relationship management, marketing, and analytics platforms.
  • Partner with the Information Technology Commercial Lead to create data architecture that tracks and reports commercial progress across launch functions.
  • Partner with Information Technology and Finance to establish a commercial view within the master data management framework so supply chain, quality, and commercial teams share a customer record.
  • Drive adoption of performance analytics and reporting tools across the commercial team so insights are accessible to field and marketing users.
Desired Qualifications
  • Experience launching United States vaccines and/or specialty biologics is highly preferred.
  • An MBA or other advanced degree is highly desired.

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections such as pneumococcal disease, Group A Strep, and Shigella. Using a proprietary cell-free protein synthesis platform called XpressCF™, the company attaches bacterial components to carrier proteins to trigger an immune response without the limitations of traditional cell-based manufacturing. This technology allows Vaxcyte to include more bacterial strains in a single dose than its competitors, as seen in their lead candidate which targets 24 different strains. The company's goal is to protect children and adults from life-threatening infections by creating vaccines that overcome complex bacterial defense mechanisms.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Get referred to Vaxcyte

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 enrollment completion removed major execution risk across three Phase 3 trials.
  • VAX-A1 entered first-in-human dosing in June 2026, expanding the pipeline beyond pneumococcus.
  • PCV31 adult data could support a BLA submission and U.S. commercial launch in 2027.

What critics are saying

  • OPUS-1 topline data lands in Q4 2026; any miss crushes VAX-31's valuation.
  • June 30, 2026 cash was $2.51 billion, but operating burn stays punishing.
  • VAX-31 failure leaves Vaxcyte a pre-revenue vaccine company with no approved products.

What makes Vaxcyte unique

  • Vaxcyte's XpressCF platform and 31-valent PCV31 target higher serotype coverage than PCV20.
  • OPUS-1, OPUS-2, and OPUS-3 fully enrolled 6,191 adults by August 2026.
  • Thermo Fisher's up to $1 billion U.S. fill-finish deal secures commercial manufacturing capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

1%
Yahoo Finance
Jun 1st, 2026
Vaxcyte completes VAX-31 Phase 3 trial enrollment, shares rise 8.7%

Vaxcyte shares rose 8.7% after completing enrollment for three Phase 3 adult trials of its VAX-31 pneumococcal vaccine candidate and a Phase 2 infant study. The company also announced plans to begin a Phase 1 adult trial for its VAX-A1 Group A Strep programme. The milestone reduces execution risk whilst advancing Vaxcyte's two-pillar strategy targeting both adult and paediatric pneumococcal markets. The company's narrative projects $224.6 million revenue by 2029, representing an earnings increase of approximately $794.7 million from current levels. Some analysts forecast Vaxcyte reaching $424 million revenue by 2029. Key near-term catalysts include OPUS-1 Phase 3 adult data readout, though higher research and manufacturing spending may pressure the company's cash runway before late-stage outcomes are determined.

GlobeNewswire
Apr 7th, 2026
Vaxcyte to present at the 25th Annual Needham Virtual Healthcare Conference.

Vaxcyte to present at the 25th Annual Needham Virtual Healthcare Conference. April 07, 2026 16:05 ET | Source: Vaxcyte, Inc. SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) - Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company's carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company's PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF(R), its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company's system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte's pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com. Jeff Macdonald, Executive Director, Investor Relations Vaxcyte, Inc. 917-371-0940 [email protected]

MJH Life Sciences
Mar 28th, 2026
Vaxcyte announces significant development of first-of-its-kind PCV31.

Vaxcyte announces significant development of first-of-its-kind PCV31. With the OPUS-1, 2, and 3 trials underway, Vax-31 has the potential to become the first pneumococcal vaccine of its kind, demonstrating never-before-seen impacts on disease burden. Vaxcyte recently announced significant progress in the clinical development of VAX-31, its 31-valent pneumococcal conjugate vaccine (PCV31) candidate, according to a news release.[1] As the highest-valent PCV currently under development, VAX-31 is being positioned as a potential best-in-class protection against pneumococcal disease for both adults and infants. "The continued advancement of VAX-31 in adults reflects disciplined execution across our phase 3 clinical program, which was finalized in consultation and alignment with the FDA, as we work toward delivering a best-in-class, next-generation PCV with the potential to set a new standard of care for adults and children," Grant Pickering, CEO and co-founder of Vaxcyte, said in the news release. "In adults, evaluating VAX-31 in settings that reflect real-world vaccination practice, including coadministration with a seasonal influenza vaccine and in individuals with prior pneumococcal vaccination, will provide important insights into how VAX-31 is expected to perform across the adult population." Dosing has commenced in the phase 3 OPUS-2 trial, which evaluates the vaccine's performance when administered concomitantly with seasonal influenza vaccines in pneumococcal-naïve adults 50 years and older. Simultaneously, Vaxcyte completed enrollment for a phase 2 infant dose-finding study, marking a critical step toward addressing the leading cause of vaccine-preventable deaths in children under 5 globally.[1] For pharmacists, who serve as the most accessible members of the health care team, these advancements represent a vital expansion of the tools available to combat infectious disease burden, which saw invasive pneumococcal disease (IPD) incidence nearly double between 2012 and 2024.[2,3] The clinical relevance of VAX-31 is underscored by its design to cover approximately 95% of invasive pneumococcal disease (IPD)-causing serotypes circulating in US adults over 50 years.[1] This broad spectrum is necessary because, despite the efficacy of current options like PCV20 and the recently approved PCV21, the phenomenon of serotype replacement continues to push nonvaccine serotypes into prominence.[3] To provide pharmacists and the FDA with real-world data, the OPUS-2 trial utilizes a randomized, double-blind approach to compare concomitant and sequential administration with flu shots, and the upcoming OPUS-3 study will specifically evaluate VAX-31 in adults who have previously received other pneumococcal vaccines, such as the 23-valent pneumococcal polysaccharide vaccine (PPSV23) or PCV20.[1] The push for higher valency, however, brings technical challenges regarding immunogenicity. Research comparing earlier vaccines like PCV7 and PCV13 with newer PCV15 and PCV20 formulations suggested that increasing the number of polysaccharides can sometimes result in lower antibody responses for common serotypes, according to the Canada Communicable Disease Report.[4] To mitigate this, some pipeline candidates - such as Inventprise's PCV25 - are utilizing innovative hydrazide-polyethylene glycol-hydrazide (Hz-PEG-Hz) linker technology to reduce carrier-induced immune interference.[2] Vaxcyte's own platform similarly aims to maintain robust immune responses while expanding coverage, a necessity as the CDC recently lowered the routine vaccination age to 50 years old.[1,5,6] In the pediatric sector, VAX-31 is designed to protect against approximately 92% of IPD serotypes and 96% of acute otitis media cases in children.[1] This is particularly important because PCVs provide nasal immunity by stimulating antibodies in the nasal mucosa, which prevents colonization and is a feature missing from PPSV23.[6] Furthermore, dosing schedules remain a point of clinical discussion, and the World Health Organization supports a 2+1 schedule for healthy children. However, some data indicates that a 3+1 schedule provides superiority.[4] Vaxcyte's ongoing infant study follows the 4-dose series to ensure maximum protection.[1] As the landscape shifts toward sophisticated platforms like Vaxcyte's cell-free protein synthesis system, the goal remains a serotype-independent vaccine - the holy grail of the pneumococcal vaccine industry.[1,7] Pharmacists can bridge current gaps by using the PneumoRecs VaxAdvisor app to navigate complex guidelines and stay updated on Vaxcyte's expanding pipeline, which also includes candidates for Group A Streptococcus and Shigella.[1,2,5] With Vaxcyte committing up to $1 billion toward US manufacturing, the infrastructure is being set to support these next-generation preventions.[1] "We expect to announce topline data from the ongoing OPUS-1 Phase 3 pivotal, noninferiority trial in the fourth quarter of 2026 and results from these additional Phase 3 adult studies in the first half of 2027, keeping us on track toward a planned Biologics License Application submission," concluded Pickering, according to the release. Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for its. References. 1. Vaxcyte advances adult and infant programs for VAX-31, a potential best-in-class, next-generation pneumococcal conjugate vaccine. News release. Vaxcyte, inc. january 22, 2026. Accessed march 18, 2026. https://www.biospace.com/press-releases/vaxcyte-advances-adult-and-infant-programs-for-vax-31-a-potential-best-in-class-next-generation-pneumococcal-conjugate-vaccine. 2. Nowosielski B. New 25-valent pneumococcal vaccine shows promise in global disease coverage. Drug Topics. March 13, 2026. Accessed march 18, 2026. https://www.drugtopics.com/view/new-25-valent-pneumococcal-vaccine-shows-promise-in-global-disease-coverage. 3. Nowosielski B. Rise in IPD calls for development of more pneumococcal vaccines. Drug Topics. November 17, 2025. Accessed march 18, 2026. https://www.drugtopics.com/view/rise-in-ipd-calls-for-development-of-more-pneumococcal-vaccines. 4. De wals P. PCV13, PCV15 or PCV20: which vaccine is best for children in terms of immunogenicity? Can commun dis rep. 2024 jan 1;50(1-2):35-39. doi: 10.14745/ccdr.v50i12a04. 5. Pneumococcal vaccine recommendations. CDC. February 25, 2026. Accessed march 18, 2026. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html. 6. Katella K. Should i get the pneumococcal vaccine? 5 things to know. Yale medicine. December 12, 2024. Accessed march 18, 2026. https://www.yalemedicine.org/news/should-i-get-the-pneumococcal-vaccine-5-things-to-know. 7. Musher DM, anderson R, feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. Pneumonia (nathan). 2022 sep 25;14(1):5. doi: 10.1186/s41479-022-00097-y. Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Simply Wall St
Mar 8th, 2026
Vaxcyte reports $766M loss and raises $408M in follow-on offering amid widening cash burn

Vaxcyte reported a full-year 2025 net loss of $766.63 million and completed a $408.1 million follow-on equity offering in February 2026. The biotech company also filed an additional $500 million at-the-market programme and a $473.86 million shelf registration for employee stock plans. The funding moves underscore Vaxcyte's reliance on equity financing to support its pneumococcal vaccine pipeline, particularly its OPUS Phase 3 programme for VAX-31. Whilst the capital raises improve funding flexibility, they raise concerns about shareholder dilution and mounting cash burn. Simply Wall St community fair value estimates for Vaxcyte range widely from $10.90 to $109 per share. The company's shares may be trading 35% above fair value despite recent declines, according to the analysis.

Vaxcyte
Feb 3rd, 2026
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Vaxcyte, Inc.

SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share.